Transdermal buprenorphine for moderate chronic noncancer pain syndromes

References

• Birse T, Lander J. Prevalence of chronic pain. Can J Public Health. 1998;89(2):129–131.
   PubMed Web of Science ®Google Scholar
• Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287–333.
   PubMed Web of Science ®Google Scholar
• Nahin R. Estimates of pain prevalence and severity in adults: United States 2012. J Pain. 2015;16:769–780.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO’s pain ladder for adults. Geneva (Switzerland): World Health Organization; 1988 [cited 2013 May 7]. Available from: http://www.who.int/cancer/palliative/painladder/en/
   Google Scholar
• Food and Drug Administration. Acetaminophen toxicity. Silver Spring (MD): Food and Drug Administration; 2013 [updated 2013 Aug 6; cited 2013 Sep 1]. Available from: http://www.fda.gov/drugs/drugsafety/ucm230396.htm.
   Google Scholar
• Yoon E, Babar A, Choudhary M, et al. Acetaminophen-induced hepatotoxicity: a comprehensive update. J Clin Transl Hepatol. 2016 Jun 28;4(2):131–142.
   PubMed Web of Science ®Google Scholar
• Yuan L, Kaplowitz N. Mechanisms of drug-induced liver injury. Clin Liver Dis. 2013 Nov;17(4):507–518.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Husni ME, Libby PA, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial. Am J Med. 2017 Dec;130(12):1415–1422.e4. doi: 10.1016/j.amjmed.2017.06.028. Epub 2017 Jul 26.
   Google Scholar
• Ong HT, Ong LM, Tan TE, et al. Cardiovascular effects of common analgesics. Med J Malaysia. 2013 Apr;68(2):189–194.
   PubMedGoogle Scholar
• Goldstein JL. Challenges in managing NSAID-associated gastrointestinal tract injury. Digestion. 2004;69(Suppl 1):25–33.
   PubMedGoogle Scholar
• Manchikanti L, Helm S 2nd, Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 2012 Jul;15(3 Suppl):ES9–38.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich T, Cdc RC. Guideline for prescribing opioids for chronic pain – United States, 2016. MMWR Recomm Rep. 2016 March 18; 65(1):1–49.
   PubMed Web of Science ®Google Scholar
• Mastropietro DJ, Omidian H. Abuse-deterrent formulations: part 2: commercial products and proprietary technologies. Expert Opin Pharmacother. 2015 Feb;16(3):305–323.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Abuse-deterrent opioid medications. Rockville (MD): FDA; 2017 [cited 2017 Mar 31]. Available from: https://www.fda.gov/newsevents/newsroom/factsheets/ucm514939.htm.
   Google Scholar
• Lubiprostone (Amitiza) for opioid-induced constipation. Med Lett Drugs Ther. 2013 Jun 10;55(1418):47–48.
   PubMed Web of Science ®Google Scholar
• Targinact–opioid pain relief without constipation? Drug Ther Bull. 2010 Dec;48(12):138–141.
   PubMedGoogle Scholar
• Methylnaltrexone (Relistor) for opioid induced constipation. Med Lett Drugs Ther. 2008 Aug 11;50(1292):63–64.
   PubMed Web of Science ®Google Scholar
• Managing opioid-induced constipation. Nursing. 2008 Jul;38(7):55.
   Google Scholar
• Methylnaltrexone: MNTX. Drugs R D. 2006;7(6):374–378.
   PubMedGoogle Scholar
• Naloxegol (Movantik) for opioid-induced constipation. JAMA. 2016;315(2):194–195.
   PubMed Web of Science ®Google Scholar
• DEA. Buprenorphine. Washington (DC): Drug Enforcement Administration; 2013 [cited 2014 Apr 24]. Available from: http://www.deadiversion.usdoj.gov/drug_chem_info/buprenorphine.pdf.
   Google Scholar
• Pat Moore Foundation. Suboxone: a history of drug treatment that works. Pat Moore Foundation; 2017. Orange County, CA. [cited 2017 Dec 7]. Available from: https://www.patmoorefoundation.com/blog/suboxone-history-drug-treatment-works.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Buprenorphine: Substance Abuse And Mental Health Services Administration; 2017 [cited 2017 Dec 7]. Available from: https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine.
   Google Scholar
• Downing JW, Leary WP, White ES. Buprenorphine: a new potent long-acting synthetic analgesic. Comparison with morphine. Br J Anaesth. 1977 Mar;49(3):251–255.
   PubMed Web of Science ®Google Scholar
• Raffa RB, Haidery M, Huang HM, et al. The clinical analgesic efficacy of buprenorphine. J Clin Pharm Ther. 2014 Dec;39(6):577–583.
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010 Sep-Oct;10(5):428–450.
   PubMed Web of Science ®Google Scholar
• Drugbank. Buprenorphine. Alberta (Canada): Canadian Institutes of Health Research; 2017 [cited 2017 Dec 8]. Available from: https://www.drugbank.ca/drugs/DB00921.
   Google Scholar
• Butler S. Buprenorphine–clinically useful but often misundestood. Scand J Pain. 2013;4(3):148–152.
   PubMedGoogle Scholar
• Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009 Mar;13(3):219–230.
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008 Jul-Aug;8(4):287–313.
   PubMedGoogle Scholar
• Vanderah TW, Gardell LR, Burgess SE, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci. 2000 Sep 15;20(18):7074–7079.
   PubMed Web of Science ®Google Scholar
• Induru RR, Davis MP. Buprenorphine for neuropathic pain–targeting hyperalgesia. Am J Hosp Palliat Care. 2009 Dec-2010 Jan;26(6):470–473.
   PubMed Web of Science ®Google Scholar
• Khanna IK, Pillarisetti S. Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. 2015;8:859–870.
   PubMed Web of Science ®Google Scholar
• Hallinan R, Byrne A, Agho K, et al. Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. Int J Androl. 2009 Apr;32(2):131–139.
   PubMed Web of Science ®Google Scholar
• Reddy RG, Aung T, Karavitaki N, et al. Opioid induced hypogonadism. Bmj. 2010;341:c4462.
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Pergolizzi J, Raffa RB, et al. The unsolved case of “bone-impairing analgesics”: the endocrine effects of opioids on bone metabolism. Ther Clin Risk Manag. 2015;11:515–523.
   PubMed Web of Science ®Google Scholar
• eMC. Transtec 35, 52.5, and 70 micrograms transdermal patch: datapharm; 2017 [cited 2017 Dec 8]. Available from: https://www.medicines.org.uk/emc/medicine/8864.
   Google Scholar
• Evans HC, Easthope SE. Transdermal buprenorphine. Drugs. 2003;63(19): 1999–2010; discussion 2011–2012.
   PubMed Web of Science ®Google Scholar
• Markman JD, Barbosa WA, Gewandter JS, et al. Interpretation of urine drug testing results in patients using transdermal buprenorphine preparations for the treatment of chronic noncancer pain. Pain Med. 2015 Jun;16(6):1132–1136.
   PubMed Web of Science ®Google Scholar
• Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice – a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin. 2005 Aug;21(8):1147–1156.
   PubMed Web of Science ®Google Scholar
• Likar R, Sittl R. Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg. 2005 Mar;100(3):781–785, table of contents.
   PubMed Web of Science ®Google Scholar
• Al-Tawil N, Odar-Cederlof I, Berggren AC, et al. Pharmacokinetics of transdermal buprenorphine patch in the elderly. Eur J Clin Pharmacol. 2013 Feb;69(2):143–149.
   PubMed Web of Science ®Google Scholar
• Kapil RP, Cipriano A, Friedman K, et al. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels. J Pain Symptom Manage. 2013 Jul;46(1):65–75.
   PubMed Web of Science ®Google Scholar
• Wang Y, Cipriano A, Munera C, et al. Dose-dependent flux of buprenorphine following transdermal administration in healthy subjects. J Clin Pharmacol. 2016 Oct;56(10):1263–1271.
   PubMed Web of Science ®Google Scholar
• Gianni W, Madaio AR, Ceci M, et al. Transdermal buprenorphine for the treatment of chronic noncancer pain in the oldest old. J Pain Symptom Manage. 2011 Apr;41(4):707–714.
   PubMed Web of Science ®Google Scholar
• Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther. 2010 May;32(5):844–860.
   PubMed Web of Science ®Google Scholar
• Landau CJ, Carr WD, Razzetti AJ, et al. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Clin Ther. 2007 Oct;29(10):2179–2193.
   PubMed Web of Science ®Google Scholar
• Likar R, Lorenz V, Korak-Leiter M, et al. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Clin Ther. 2007 Aug;29(8):1591–1606.
   PubMed Web of Science ®Google Scholar
• Munera C, Drehobl M, Sessler NE, et al. A randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritis. J Opioid Manag. 2010 May-Jun;6(3):193–202.
   PubMedGoogle Scholar
• Simpson RW, Wlodarczyk JH. Transdermal buprenorphine relieves neuropathic pain: a randomized, double-blind, parallel-group, placebo-controlled trial in diabetic peripheral neuropathic pain. Diabetes Care. 2016 Sep;39(9):1493–1500.
   PubMed Web of Science ®Google Scholar
• Steiner D, Munera C, Hale M, et al. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. J Pain. 2011 Nov;12(11):1163–1173.
   PubMed Web of Science ®Google Scholar
• Steiner DJ, Sitar S, Wen W, et al. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2011 Dec;42(6):903–917.
   PubMed Web of Science ®Google Scholar
• Gatti A, Dauri M, Leonardis F, et al. Transdermal buprenorphine in non-oncological moderate-to-severe chronic pain. Clin Drug Investig. 2010;30(Suppl 2):31–38.
   PubMed Web of Science ®Google Scholar
• Yarlas A, Miller K, Wen W, et al. Buprenorphine transdermal system improves sleep quality and reduces sleep disturbance in patients with moderate-to-severe chronic low back pain: results from two randomized controlled trials. Pain Pract. 2016 Mar;16(3):345–58. doi: 10.1111/papr.12281. Epub 2015 Jan 20.
   Google Scholar
• Serpell M, Tripathi S, Scherzinger S, et al. Assessment of transdermal buprenorphine patches for the treatment of chronic pain in a UK Observational Study. Patient. 2016 Feb;9(1):35–46.
   PubMedGoogle Scholar
• Uberall MA, Muller-Schwefe GH. Low-dose 7-day transdermal buprenorphine in daily clinical practice – perceptions of elderly patients with moderate non-malignant chronic pain. Curr Med Res Opin. 2012 Oct;28(10):1585–1595.
   PubMed Web of Science ®Google Scholar
• Kapil RP, Cipriano A, Michels GH, et al. Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system. Clin Drug Investig. 2012 Sep 1;32(9):583–592.
   PubMed Web of Science ®Google Scholar
• Yoon DH, Bin SI, Chan SK, et al. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain. BMC Musculoskelet Disord. 2017 Aug 4;18(1):337.
   PubMedGoogle Scholar
• Coplan PM, Sessler NE, Harikrishnan V, et al. Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System. Postgrad Med. 2017 Jan;129(1):55–61.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr., Scholten W, Smith KJ, et al. The unique role of transdermal buprenorphine in the global chronic pain epidemic. Acta Anaesthesiol Taiwan. 2015 Jun;53(2):71–76.
   PubMedGoogle Scholar
• Sessler NE, Walker E, Chickballapur H, et al. Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data. Postgrad Med. 2017 Jan;129(1):62–68.
   PubMed Web of Science ®Google Scholar
• James IG, O’Brien CM, McDonald CJ. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. J Pain Symptom Manage. 2010 Aug;40(2):266–278.
   PubMed Web of Science ®Google Scholar
• Karlsson M, Berggren AC. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther. 2009 Mar;31(3):503–513.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, O’Brien CM, Wilson M, et al. Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial. Osteoarthritis Cartilage. 2011 Aug;19(8):930–938.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Serpell M, McSkimming P, et al. Satisfaction, adherence and health-related quality of life with transdermal buprenorphine compared with oral opioid medications in the usual care of osteoarthritis pain. Patient. 2016 Aug;9(4):359–371.
   PubMedGoogle Scholar
• Lee JH, Kim JH, Kim JH, et al. Efficacy and safety of transdermal buprenorphine versus oral tramadol/acetaminophen in patients with persistent postoperative pain after spinal surgery. Pain Res Manag. 2017;2017:2071494. doi: 10.1155/2017/2071494. Epub 2017 Sep 13.
   Web of Science ®Google Scholar
• Centers for Disease C, Prevention. CDC grand rounds: prescription drug overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012 Jan 13;61(1):10–13.
   PubMedGoogle Scholar
• Wightman R, Perrone J, Portelli I, et al. Likeability and abuse liability of commonly prescribed opioids. J Med Toxicol. 2012;8(4):335–340.
   PubMedGoogle Scholar
• Manchikanti L, Fellows B, Damron KS, et al. Prevalence of illicit drug use among individuals with chronic pain in the Commonwealth of Kentucky: an evaluation of patterns and trends. J Ky Med Assoc. 2005 Feb;103(2):55–62.
   PubMedGoogle Scholar
• Abuse N. Trends & stastistics. Washington (DC):National Institutes of Health. 2017 [cited 2017 Dec 14]. Available from: https://www.drugabuse.gov/related-topics/trends-statistics.
   Google Scholar
• Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. Anesth Analg. 2007 Jul;105(1):205–221.
   PubMed Web of Science ®Google Scholar
• Daher M. Pain relief is a human right. Asian Pac J Cancer Prev. 2010 Apr;11 Suppl 1:97–101.
   PubMedGoogle Scholar
• International Pain Summit of the International Association for the Study of P. Declaration of Montreal: declaration that access to pain management is a fundamental human right. J Pain Palliat Care Pharmacother. 2011;25(1):29–31.
   PubMedGoogle Scholar
• Anson P. CDC: painkillers no longer driving opioid epidemic. La Crescenta (CA): Pain Week News Network; 2017.
   Google Scholar